GEMMs introduce key oncogenic drivers, such as TP53 loss or β-catenin activation, but typically fail to recapitulate the chronic inflammation, cirrhosis, and fibrosis that define the clinical HCC context [114]. The gene discussed is TP53; the disease is Cirrhosis.